November 22, 2024 07:19 GMT
HEALTHCARE: Glaxo (GSK: A2/A): Arexvy Age Extension - Japan
HEALTHCARE
- Welcome news from Japan. Won't move spreads today but helps at the margins.
- Arexvy is hoped to have over £3bn peak annual sales eventually
- Last quarter sold £188m - which was seen as a disappointment
- Japan has extended its use to the 50-59 age bracket from just >60 previously
- The FDA expanded the age category in June
- GSK's latest quarterly results saw weak take-up of the vaccine so any good news on the age extension will be welcome
73 words